With a purpose-driven culture and innovation at its core, Inceptor Bio is committed to confronting one of humanity’s single most complex problems — difficult-to-cure cancers. Every day, we are working to enable patients with these cancers to realize what was once an impossible dream — to be cured.
Led by scientific and industry pioneers, Inceptor Bio is developing next-generation cell therapy programs with a focus on chimeric antigen receptor (CAR) constructs, which have novel mechanisms to enhance immune cell activation and endurance in the tumor microenvironment (TME).
We are developing best-in-class therapies – our CAR-T, CAR-M, CAR-NK platform technologies – to enhance the likelihood of success against difficult-to-treat cancers.
Seizing the moment in this time of unprecedented technical development in synthetic biology, we are leveraging the biological, bioinformatic, and technical advances to bring new cures to those in need. Inceptor Bio is differentiated by a team with experience developing cell therapies, and a great depth of scientific and manufacturing knowledge, backed by cutting edge resources.
Cell therapy is a rapidly growing and evolving industry. Inceptor Bio has built a team that has unique and extensive industry expertise. It is comprised of highly committed individuals, capable of taking programs from preclinical through the clinic and beyond. What draws this team together is a shared passion to realize the tremendous potential of cell and gene therapies to deliver cures for cancer patients.
The other key pillar of Inceptor Bio’s strategy is alleviating what has been a major bottleneck for cell therapies – access to early-phase manufacturing. We have established our Advance Manufacturing Platform (AMP+), based in Gainesville, Florida. Guided by the vision of our expert team, it offers a highly flexible, configurable concept of manufacturing and features the latest state-of-the-art technologies for cell therapy manufacturing with scalability and expansion capabilities.